Comparative Pharmacology
Head-to-head clinical analysis: DARZALEX versus DARZALEX FASPRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARZALEX versus DARZALEX FASPRO.
DARZALEX vs DARZALEX FASPRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daratumumab is an IgG1κ human monoclonal antibody that binds to CD38, a transmembrane glycoprotein highly expressed on the surface of multiple myeloma cells. Binding to CD38 induces apoptosis via immune-mediated mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).
Daratumumab is a human IgG1κ monoclonal antibody that binds to CD38, a transmembrane glycoprotein highly expressed on the surface of multiple myeloma cells. It induces tumor cell death through multiple mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis via cross-linking. It also reduces the activity of CD38-positive immunosuppressive cells (e.g., regulatory T cells, B cells, and myeloid-derived suppressor cells).
16 mg/kg intravenously once weekly for weeks 1-8, then every 2 weeks for weeks 9-24, then every 4 weeks starting week 25 until disease progression. Subcutaneous formulation: 1800 mg subcutaneously once weekly for weeks 1-8, then every 2 weeks for weeks 9-24, then every 4 weeks starting week 25.
Daratumumab 1800 mg subcutaneously over 3-5 minutes once weekly for 8 weeks, then every 2 weeks for 8 doses, then every 4 weeks thereafter. Administered in combination with hyaluronidase (fixed dose 30,000 U).
None Documented
None Documented
Mean terminal half-life is approximately 18 days (range 12–28 days) after the last dose, supporting an every-4-week maintenance dosing interval.
Terminal elimination half-life is approximately 16 days (range 11–22 days) after subcutaneous administration of DARZALEX FASPRO, supporting once-monthly dosing due to prolonged target-mediated clearance.
Daratumumab is eliminated primarily via intracellular catabolism and proteolytic degradation. No significant renal or biliary excretion occurs. Less than 1% of the dose is excreted unchanged in urine.
Daratumumab is eliminated primarily through intracellular catabolism and subsequent proteolytic degradation; renal excretion is minimal (<1% of dose as unchanged drug in urine), biliary/fecal excretion is negligible.
Category C
Category C
CD38-directed Monoclonal Antibody
CD38-directed Monoclonal Antibody